Ana Matilla
YOU?
Author Swipe
View article: Breaking Barriers for Intensive Care Admission in Patients With Advanced <scp>HCC</scp> on Immunotherapy
Breaking Barriers for Intensive Care Admission in Patients With Advanced <span>HCC</span> on Immunotherapy Open
Background and Aims Intensive Care Unit (ICU) admission is usually denied to patients with advanced hepatocellular carcinoma (HCC) due to the perceived poor prognosis associated with both cirrhosis and liver cancer. However, immunotherapy …
View article: Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial Open
Background The health-related quality of life (HRQoL) impact of therapies for hepatocellular carcinoma (HCC) influences decision-making and treatment outcomes. The present study reports HRQoL results from NASIR-HCC, a single-arm study of s…
View article: Evolving epidemiology of HCC in Spain
Evolving epidemiology of HCC in Spain Open
Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, mor…
View article: Internal and external validation of indocyanine green plasma disappearance rate to discard liver grafts before procurement
Internal and external validation of indocyanine green plasma disappearance rate to discard liver grafts before procurement Open
ICG clearance test performed in DBD was internally and externally validated to predict liver graft discard. It could be used as a screening tool before donation to avoid unnecessary costs of travel and human resources.
View article: Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 Open
View article: Ácido úrico y daño renal agudo en pacientes con alto riesgo de desarrollar daño renal agudo sometidos a cirugía cardiaca: cohorte prospectiva multicéntrica
Ácido úrico y daño renal agudo en pacientes con alto riesgo de desarrollar daño renal agudo sometidos a cirugía cardiaca: cohorte prospectiva multicéntrica Open
No está claro si la elevación de ácido úrico sérico (AUS) preoperatorio puede desempeñar un papel en el desarrollo de daño renal agudo (DRA) asociado a cirugía cardiaca (DRA-CS). Se realizó un estudio de cohortes para evaluar la influencia…
View article: Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial Open
PURPOSE To investigate the safety and efficacy of nivolumab plus cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. METHODS In cohort 6 of the multicohort, open-label, phase I/II CheckMate 040 study…
View article: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study Open
Purpose To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor in patients with unresectable hepatocellular carcinoma (uHCC) and liver-only disease ineligible for chemoemboli…
View article: Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose.
Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. Open
View article: THE COMPLEX MANAGEMENT OF HEPATOCELLULAR CARCINOMA: A MAJOR NEED OF EXPERTISE
THE COMPLEX MANAGEMENT OF HEPATOCELLULAR CARCINOMA: A MAJOR NEED OF EXPERTISE Open
Hepatocellular carcinoma (HCC) is the most frequent liver primary cancer and represents the sixth malignant neoplasm and the fourth cause of cancer associated deaths worldwide. Despite improvements across the last years in therapeutic opti…
View article: CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis Open
View article: Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH
Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH Open
tHepatocellular carcinoma (HCC) is the most common primary liver neoplasm and one of the most com-mon causes of death in patients with cirrhosis of the liver. In parallel, with recognition of the clinicalrelevance of this cancer, major new…
View article: Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice Open
View article: Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Open
ClinicalTrials.gov Identifier: NCT01658878.
View article: Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis
Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis Open
View article: Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040
Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 Open
View article: International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis
International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis Open
Background & Aims Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma (HCC) under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, preva…
View article: Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen
Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen Open
View article: Is it reasonable to perform Fecal Microbiota Transplantation for recurrent Clostridium difficile Infection in patients with liver cirrhosis?
Is it reasonable to perform Fecal Microbiota Transplantation for recurrent Clostridium difficile Infection in patients with liver cirrhosis? Open
View article: IL‐1 Receptor Antagonist in Combination with Pentoxifylline and Zinc for Severe Alcoholic Hepatitis: A Multicenter Randomized Double‐Bind Placebo‐Controlled Clinical Trial
IL‐1 Receptor Antagonist in Combination with Pentoxifylline and Zinc for Severe Alcoholic Hepatitis: A Multicenter Randomized Double‐Bind Placebo‐Controlled Clinical Trial Open
Background: recently, the Baveno VI guidelines have suggested that esophagogastroduodenoscopy (EGD) to stage esophageal varices can be avoided in patients with advanced liver disease who have a liver stiffness (LS) 150x103/μL. Our study ai…
View article: Is it Reasonable to Perform Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients with Liver Cirrhosis?
Is it Reasonable to Perform Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients with Liver Cirrhosis? Open
Maria Olmedo, Elena Reigadas, Maricela Valerio, Silvia Vazquez-Cuesta, Jose Antonio Pajares, Ana Matilla, Patricia Munoz and Emilio Bouza-Is it Reasonable to Perform Fecal Microbiota Transplantation for Recurrent Clostridium difficile<…
View article: Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events Open
The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due to the absence of complete responses, even though patients who develop early dermatologic reactions have shown to have a positive ou…
View article: Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008–2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers
Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008–2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers Open
In 2010 we published that 53% of cases of hepatocellular carcinoma (HCC) detected in Spain were diagnosed outside the context of standard screening programs, which consequently leads to lower survival rates. The aim of this study was to an…
View article: Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros
Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros Open